Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Eidos Therapeutics Inc (EIDX)

Eidos Therapeutics Inc (EIDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,750,670
  • Shares Outstanding, K 38,873
  • Annual Sales, $ 26,690 K
  • Annual Income, $ -37,840 K
  • 60-Month Beta -0.16
  • Price/Sales 36,543.62
  • Price/Cash Flow N/A
  • Price/Book 38.46
Trade EIDX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.65
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/24/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.77
  • Number of Estimates 3
  • High Estimate -0.74
  • Low Estimate -0.81
  • Prior Year -0.51
  • Growth Rate Est. (year over year) -50.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
116.24 +5.14%
on 01/05/21
132.54 -7.79%
on 01/04/21
-5.49 (-4.30%)
since 12/24/20
3-Month
69.38 +76.16%
on 10/30/20
132.54 -7.79%
on 01/04/21
+48.92 (+66.75%)
since 10/23/20
52-Week
28.39 +330.47%
on 03/16/20
132.54 -7.79%
on 01/04/21
+68.05 (+125.65%)
since 01/24/20

Most Recent Stories

More News
BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial Officer

REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of...

BMEA : 9.78 (+2.84%)
EIDX : 122.21 (-4.85%)
BBIO : 9.94 (-2.55%)
IOVA : 9.58 (+0.52%)
BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update

– Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory...

BBIO : 9.94 (-2.55%)
EIDX : 122.21 (-4.85%)
BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc.

PALO ALTO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of...

BBIO : 9.94 (-2.55%)
EIDX : 122.21 (-4.85%)
Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc.

PALO ALTO, Calif. and SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) today announced...

BBIO : 9.94 (-2.55%)
EIDX : 122.21 (-4.85%)
BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Announce January 21, 2021 Election Deadline for Merger

PALO ALTO, Calif. and SAN FRANCISCO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) announced today...

BBIO : 9.94 (-2.55%)
EIDX : 122.21 (-4.85%)
EIDOS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of EIDX and Encourages Investors to Contact the Firm

NEW YORK, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Eidos Therapeutics,...

EIDX : 122.21 (-4.85%)
BBIO : 9.94 (-2.55%)
Leading Independent Proxy Advisory Firm ISS Recommends BridgeBio Pharma and Eidos Therapeutics Stockholders Vote “FOR” Proposed Merger

PALO ALTO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced that leading proxy advisory firm Institutional Shareholder Services (“ISS”) recommends that...

BBIO : 9.94 (-2.55%)
EIDX : 122.21 (-4.85%)
Lifshitz Law Firm, P.C. Announces Investigation of EIDX, NAV, STND, and WTRE

NEW YORK, NY / ACCESSWIRE / January 3, 2021 / Lifshitz Law Firm, P.C.: Eidos Therapeutics, Inc. (NASDAQ:EIDX) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in...

EIDX : 122.21 (-4.85%)
NAV : 44.50 (+0.16%)
STND : 33.00 (+0.06%)
WTRE : 15.61 (+1.36%)
MERGER INVESTIGATION ALERT: Halper Sadeh LLP Encourages CKH, PS, WDR, and EIDX Shareholders to Contact the Firm

NEW YORK, NY / ACCESSWIRE / January 2, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: SEACOR Holdings Inc. (NYSE:CKH) concerning potential...

EIDX : 122.21 (-4.85%)
PS : 22.45 (+0.13%)
CKH : 41.50 (+0.22%)
WDR : 24.98 (-0.04%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers – CKH, WDR, NAV, EIDX

NEW YORK, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

CKH : 41.50 (+0.22%)
WDR : 24.98 (-0.04%)
NAV : 44.50 (+0.16%)
EIDX : 122.21 (-4.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States.

See More

Key Turning Points

3rd Resistance Point 139.85
2nd Resistance Point 134.17
1st Resistance Point 128.19
Last Price 122.21
1st Support Level 116.53
2nd Support Level 110.85
3rd Support Level 104.87

See More

52-Week High 132.54
Last Price 122.21
Fibonacci 61.8% 92.75
Fibonacci 50% 80.46
Fibonacci 38.2% 68.18
52-Week Low 28.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar